@article{JTD24247,
author = {Minoru Fukuda and Hiroyuki Yamaguchi and Hiroshi Mukae and Kazuto Ashizawa},
title = {Programmed death ligand-1 inhibitors potentially carry a lower risk of pneumonitis compared with programmed death-1 inhibitors in patients with non-small cell lung cancer},
journal = {Journal of Thoracic Disease},
volume = {10},
number = {Suppl 33},
year = {2018},
keywords = {},
abstract = {Cancer cells are attacked by innate and acquired immune mechanisms; however, they can escape from immune surveillance via various mechanisms. Immunotherapies involving monoclonal antibodies against programmed death-1 (PD-1) and programmed death ligand-1 (PD-L1); i.e., checkpoint inhibitors, have been developed to inhibit the PD-1 pathway and cause T-cells to attack cancer cells.},
issn = {2077-6624}, url = {https://jtd.amegroups.org/article/view/24247}
}